Professor and Director
UCLA, California, United States
Dr. Damoiseaux is Professor in Molecular and Medical Pharmacology and Bioengineering at the University of California-Los Angeles. He obtained his PhD in bioorganic chemistry under Kai Johnsson at the University of Lausanne before joining Novartis (GNF) where fell in love with automation, robotics and high throughput experimentation. He is now at the University of California, Los Angeles where he set up high throughput screening and drug discovery efforts. The most advanced small molecule discovered in his laboratory (TRE-515) achieved orphan drug designation in 2022 and successfully completed phase I trials at UCLA in March 2023 while the most advanced antibody DUNP19 achieved FDA Orphan Drug Designation in September 2022. Expert at assay development, automation, technology development, data handling and analysis, he enjoys teaching our next generation of scientists the foundations and intricacies of automation at the interface of biology, chemistry and artificial intelligence.
Disclosure information not submitted.
Tuesday, February 8, 2022
3:00 PM – 4:00 PM